Mallinckrodt to divest BioVectra for £202m
The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as well as contingent
Novartis has signed an agreement to acquire SNV4818, a pan-mutant selective Phosphoinositide 3-kinase alpha (PI3Kα) inhibitor, from Synnovation Therapeutics.
“We’re pleased that the FDA has granted this designation for sotatercept,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron. “In preclinical studies,
The FDA grants Priority Review designation to applications for medicines that have the potential to provide significant improvements in the treatment of serious conditions. Priority Review is associated
Imfinzi, along with four cycles of standard-of-care (SoC) chemotherapy, showed a statistically-significant and clinically-meaningful improvement in OS against SoC including up to six cycles of chemotherapy and optional